Journal of Cardiac Failure
Volume 13, Issue 4 , Pages 241-246 , May 2007

Remote Active Monitoring in Patients With Heart Failure (RAPID-RF): Design and Rationale

  • Leslie A. Saxon, MD

      Affiliations

    • From the University of Southern California, Los Angeles, California
    • Corresponding Author InformationReprint requests: Leslie A. Saxon, MD, 1500 San Pablo Street, Second Floor, Los Angeles, CA 90033.
    • ,
  • John P. Boehmer, MD

      Affiliations

    • Hershey Medical Center, Hershey, Pennsylvania
    • ,
  • Stacey Neuman, PhD

      Affiliations

    • Boston Scientific Corporation, St. Paul, Minnesota
    • ,
  • Christopher M. Mullin, MS

      Affiliations

    • The Integra Group, Brooklyn Park, Minnesota

Received 19 October 2006 ,Revised 11 December 2006 ,Accepted 19 December 2006.

References 

  1. American Heart Association . Heart disease and stroke statistics—2005 update. Dallas (Tx): American Heart Association; 2005;
  2. Ho KK, Pinssky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22:6A–13A
  3. Croft JB, Giles WA, Pollard RA, Casper ML, Anda RF, Livengood JR. National trends in the initial hospitalization for heart failure. J Am Geriatr Soc. 1997;45:270–275
  4. Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc. 1997;45:968–974
  5. Whellan DJ, Hasselblad V, Peterson E, O'Conner CM, Schulman KA. Metaanalysis and review of heart failure disease management randomized controlled clinical trials. Am Heart J. 2005;149:722–729
  6. Cleland JG, Louis AA, Rigby AS, Janssens U, Balk AH TEN-HMS Investigators. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death. J Am Coll Cardiol. 2005;45:1654–1664
  7. HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006;12:e1–e122
  8. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-Resynchronization Therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150
  9. Reicin GM, Wittes J. Morgan Stanley equity research North American, hospital supplies and medical technology. industry overview—an investors' guide to ICDs. New York: Morgan Stanley. October 8. 2002;
  10. Kimmelstiel C, Levine D, Perry K, et al. Randomized, controlled evaluation of short- and long-term benefits of heart failure disease management within a diverse provider network. Circulation. 2004;110:1450–1455
  11. Rich MW. Heart failure disease management programs: efficacy and limitations. Am J Med. 2001;110:410–412
  12. West JA, DeBusk RF. Disease management systems for chronic cardiovascular diseases: focus on heart failure. Adv Intern Med. 2001;46:295–306
  13. Winters SL, Packer DL, Marchlinski FE, et al. Consensus statement on indications, guidelines for use, and recommendations for follow-up of implantable cardioverter defibrillators. Pacing Clin Electrophysiol. 2001;24:262–269
  14. McGrory-Usset ME, Stanton MS. Use of implantable cardioverter defibrillator (ICD) therapy and ICD guidelines around the world. In:  Ovyshcher IE editors. New development in cardiac pacing and electrophysiology. Armonk (NY): Futura Publishing Company, Inc.; 2002;p. 81–90
  15. Schoenfeld MH, Compton SJ, Mead RH, Weiss DN, Sherfesee L, Englund J, et al. Remote monitoring of implantable cardioverter defibrillators: a prospective analysis. Pacing Clin Electrophysiol. 2004;27:757–763
  16. Goldberg LR, Piette JD, Walsh MN, Frank TA, Jaski BE, Smith AL, et al. Randomized trial of a daily electronic home monitoring system in patients with advanced heart failure: The Weight Monitoring in Heart Failure (WHARF) trial. Am Heart J. 2003;146:705–712
  17. Packer M. Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. J Card Fail. 2001;7:176–182
  18. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J. 1992;124:1017–1025
  19. Bonow RO, Smaha LA, Smith SC, Mensah GA, Lenfant C. The international burden of cardiovascular disease: Responding to the emerging global epidemic. Circulation. 2002;106:1602–1605
  20. HFSA 2006 comprehensive heart failure practice guideline. J Card Fail. 2006;12:e1–e122
  21. Hunt S, Baker DW, Chin MH, Cinquegrani MP, Feldman A, Francis G, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation. 2001;104:2996–3007
  22. Heart Rhythm Society. NASPE expert consensus statement. Available from: http://hrsonline.org/swPositionStatementFiles/ps99316504.asp. Accessed April 2, 2007.

 All decisions regarding this manuscript were made by a guest editor.Sponsored in full by Boston Scientific Corporation. This trial is registered on www.clinicaltrials.gov (trial identifier: NCT00334451).Leslie A. Saxon is a paid consultant to Boston Scientific Corporation and Medtronic. John P. Boehmer is a paid consultant to Boston Scientific Corporation. Christopher M. Mullin is a paid consultant to Boston Scientific Corporation.

PII: S1071-9164(06)01296-6

doi: 10.1016/j.cardfail.2006.12.004

Journal of Cardiac Failure
Volume 13, Issue 4 , Pages 241-246 , May 2007

Article Tools

* Image Usage & Resolution